Cochrane · systematic review · CD008386
Statins for multiple sclerosis
Wang, J, Xiao, Y, Luo, M, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Statins plus beta interferon versus beta interferon for multiple sclerosis
Population: multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with relapses at 12 months Number of participants with relapses at 12 months Statins plus beta interferon vs beta interferon | RR 1 [0.45, 2.23] | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with relapses at 24 months Number of participants with relapses at 24 months Statins plus beta interferon vs beta interferon | RR 0.7 [0.36, 1.36] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with progression at 12 months3 ‐ not reported Statins plus beta interferon vs beta interferon | no estimate extracted | NR | No studies |
Number of participants with progression at 24 months Number of participants with progression at 24 months Statins plus beta interferon vs beta interferon | RR 0.13 [0.01, 2.22] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months Statins plus beta interferon vs beta interferon | RR 1 [0.3, 3.36] | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with new T2 or GELs at 24 months3 ‐ not reported Statins plus beta interferon vs beta interferon | no estimate extracted | NR | No studies |
Changes of EDSS at 12 months Changes of EDSS at 12 months Statins plus beta interferon vs beta interferon | no estimate extracted | 2 studies · 387 participants | Moderate Downgraded: risk of bias |